Aegis Capital Reaffirms Adamas Pharma (ADMS) at 'Buy'; Dyskinesia Secondary Endpoint Also Seen as Key

Go back to Aegis Capital Reaffirms Adamas Pharma (ADMS) at 'Buy'; Dyskinesia Secondary Endpoint Also Seen as Key
ADAMAS PHARMACEUT (NASDAQ: ADMS) Delayed: 8.22 --0 (-0%)
Previous Close $8.22    52 Week High $31.84 
Open $8.22    52 Week Low $12.02 
Day High $8.22    P/E N/A 
Day Low $8.22    EPS $0.00 
Volume 10,391